Target Gene Table ▼
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30005769HIVENSG00000110436.13protein_codingSLC1A2NoNo6506A2A2U1
P43004
TVIS30029340HIVENSG00000110436.13protein_codingSLC1A2NoNo6506A2A2U1
P43004
TVIS30029341HIVENSG00000110436.13protein_codingSLC1A2NoNo6506A2A2U1
P43004
TVIS20011853HPVENSG00000110436.13protein_codingSLC1A2NoNo6506A2A2U1
P43004
TVIS20014144HPVENSG00000110436.13protein_codingSLC1A2NoNo6506A2A2U1
P43004
TVIS20026937HPVENSG00000110436.13protein_codingSLC1A2NoNo6506A2A2U1
P43004
TVIS44026594HTLV-1ENSG00000110436.13protein_codingSLC1A2NoNo6506A2A2U1
P43004
TVIS44012539HTLV-1ENSG00000110436.13protein_codingSLC1A2NoNo6506A2A2U1
P43004
TCGA Plot Options ▼
Drug Information ▼
GeneSLC1A2
DrugBank IDDB00142
Drug NameGlutamic acid
Target IDBE0000884
UniProt IDP43004
Regulation Type
PubMed IDs16718509; 16959378; 17088867; 16855093
CitationsKing N, Lin H, McGivan JD, Suleiman MS: Expression and activity of the glutamate transporter EAAT2 in cardiac hypertrophy: implications for ischaemia reperfusion injury. Pflugers Arch. 2006 Sep;452(6):674-82. Epub 2006 May 23.@@Nickell J, Salvatore MF, Pomerleau F, Apparsundaram S, Gerhardt GA: Reduced plasma membrane surface expression of GLAST mediates decreased glutamate regulation in the aged striatum. Neurobiol Aging. 2007 Nov;28(11):1737-48. Epub 2006 Sep 7.@@Beart PM, O'Shea RD: Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol. 2007 Jan;150(1):5-17. Epub 2006 Nov 6.@@Glowatzki E, Cheng N, Hiel H, Yi E, Tanaka K, Ellis-Davies GC, Rothstein JD, Bergles DE: The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea. J Neurosci. 2006 Jul 19;26(29):7659-64.
GroupsApproved; Nutraceutical
Direct ClassificationGlutamic acid and derivatives
SMILESN[C@@H](CCC(O)=O)C(O)=O
PathwaysHistidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling
PharmGKBPA449776
ChEMBLCHEMBL575060